|
|||||
|
|
Activating KRAS mutation is prognostic only among patients who receive preoperative chemotherapy before resection of colorectal liver metastases |
|
| Authors: | Georgios Antonios Margonis MD PhD Yuhree Kim MD MPH Kazunari Sasaki MD Mario Samaha MD Stefan Buettner Bsc Neda Amini MD Timothy M. Pawlik MD MPH PhD FACS |
| Affiliation: | Department of Surgery, The Johns Hopkins Hospital, Baltimore, Maryland |
| Abstract: | |
| Keywords: | KRAS mutations preoperative chemotherapy CRLM |